Imunon (IMNN) Stock Price, News & Analysis

Company Overview

Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Key Stats

• Today's Range: $0.91 to $0.98
• 50-Day Range: $0.80 to $1.14
• 52-Week Range: $0.64 to $3.65
• Volume: 165,175 shs
• Average Volume: 884,186 shs
• Market Capitalization: $14.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $21.50
• Consensus Rating: Buy

Imunon Stock Analysis - MarketRank™

Imunon scored higher than 35% of companies evaluated by MarketBeat, and ranked 699th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

Imunon has received a consensus rating of Buy. The company's average rating score is 3.33, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Imunon has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Imunon are expected to grow in the coming year, from ($1.68) to ($1.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Imunon is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Imunon is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Imunon has a P/B Ratio of 0.68. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

7.17% of the float of Imunon has been sold short.

Short Interest Ratio / Days to Cover

Imunon has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Imunon has recently decreased by 4.96%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Imunon does not currently pay a dividend.

Dividend Growth

Imunon does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.17% of the float of Imunon has been sold short.

Short Interest Ratio / Days to Cover

Imunon has a short interest ratio ("days to cover") of 4.4.

Change versus previous month

Short interest in Imunon has recently decreased by 4.96%, indicating that investor sentiment is improving.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

8 people have searched for IMNN on MarketBeat in the last 30 days. This is an increase of 167% compared to the previous 30 days.

MarketBeat Follows

12 people have added Imunon to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Imunon insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.00% of the stock of Imunon is held by insiders.

Percentage Held by Institutions

Only 4.47% of the stock of Imunon is held by institutions.

IMNN Stock Analysis - Frequently Asked Questions

How have IMNN shares performed this year?

Imunon's stock was trading at $0.95 on January 1st, 2025. Since then, IMNN shares have increased by 1.1% and is now trading at $0.9601.
View the best growth stocks for 2025 here.

How were Imunon's earnings last quarter?

Imunon, Inc. (NASDAQ:IMNN) issued its quarterly earnings results on Thursday, November, 7th. The company reported ($0.34) EPS for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03.

How do I buy shares of Imunon?

Shares of IMNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Imunon own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Imunon investors own include Meta Platforms (META), Advanced Micro Devices (AMD), Energy Transfer (ET), NVIDIA (NVDA), AT&T (T), AbbVie (ABBV) and Broadcom (AVGO).

Company Calendar

• Last Earnings: 11/07/2024
• Today: 4/05/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:IMNN
• CIK: 749647
• Web: www.imunon.com
• Phone: (609) 896-9100
• Fax: 609-896-2200
• Employees: 30
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $21.50
• High Stock Price Target: $29.00
• Low Stock Price Target: $14.00
• Potential Upside/Downside: +2,139.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.33
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($1.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-19,510,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -230.05%
• Return on Assets: -128.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.30
• Quick Ratio: 2.30

Sales & Book Value

• Annual Sales: $500,000.00
• Price / Sales: 28.08
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.42 per share
• Price / Book: 0.68

Miscellaneous

• Outstanding Shares: 14,621,000
• Free Float: 13,776,000
• Market Cap: $14.04 million
• Optionable: Not Optionable
• Beta: 1.96